When Elise Felicione tried to design a clinical trial for a supplement, 5 things got in the way. It’s a lesson for the ...

FDA's Plausible Mechanism Framework streamlines individualized therapy approvals for ultra-rare diseases.

By Dr. Priyom Bose, Ph.D. Inviting adults to colorectal cancer screening at age 60 shifts diagnoses to earlier stages without ...

As rare disease trials face persistent feasibility challenges, Bayesian designs are gaining momentum by enabling more ...

This transition is explored in “Embodied Artificial Intelligence in Healthcare: A Systematic Review of Robotic Perception, ...

News headlines often compress complex science into a simple storyline: If two things are happening at the same time, one must ...

Divergence in the post-progression interval suggests disparities may concentrate in subsequent-line therapy, surveillance, supportive care, or access to timely interventions outside trial ...

In an interview, C. Ola Landgren, MD, PhD, delved into the details of the FDA's draft guidance on using MRD as a basis for ...

Protein S deficiency represents a rare but significant hereditary thrombophilia that poses substantial risks during pregnancy ...

A peer navigator intervention following a nonfatal opioid overdose in the emergency department does not significantly reduce ...

Transcript: Rare Diseases ...

Trauma and Extremities partnership aligns disciplined approach to portfolio optimization and focuses on delivering long-term ...